Trial Profile
Evaluate the Long-term (3 Months) Efficacy of L-threo DOPS (DroxiDopa) on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With Multiple System Atrophy (MSA). Comparative Study Versus Placebo
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 26 Aug 2020
Price :
$35
*
At a glance
- Drugs Droxidopa (Primary)
- Indications Orthostatic hypotension
- Focus Therapeutic Use
- Acronyms DOPS-AMS
- 24 Aug 2020 Status changed from recruiting to completed.
- 13 Nov 2019 This trial has been completed in France, according to European Clinical Trials Database record
- 07 Mar 2019 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Mar 2017)